Crossing the Canyon in Prostate Cancer
Executive Summary
Cancer drugs are hot. Sales of cancer therapies rose from $2.1 billion to $2.9 billion between 1992 and 1996, and even those figures may understate the market. Moreover, the number of cancer drugs in development has also risen dramatically. Perhaps the most fertile area of opportunity: prostate cancer, which is being boosted by an increase in consumer support, leading to faster FDA approvals, and renewed investment from Big Pharma and biotechs.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.